SCHEMBL1744984

SCHEMBL1744984

COC(=O)CCc1ccc(OC2CCc3ccc(OC)cc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 14/20 0.50
NQO2 P16083 13/20 0.48
MTNR1B P49286 13/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1747248 0.92 GRIN2B (0.44) MTNR1A
SCHEMBL1746588 0.89 FFAR1 (0.49) MTNR1ANQO2MTNR1B
SCHEMBL1744577 0.89 IDO1 (0.42) MTNR1ANQO2MTNR1B
SCHEMBL1745269 0.87 KMT2A (0.46) MTNR1ANQO2MTNR1B
SCHEMBL1745225 0.87 FFAR1 (0.52)
SCHEMBL1744681 0.87 FFAR1 (0.52)
SCHEMBL1744692 0.87 FFAR1 (0.52)
SCHEMBL1746434 0.86 RXRA (0.47)
SCHEMBL15679161 0.86 HRH3 (0.40)
SCHEMBL1747100 0.86 FFAR1 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR MTNR1A 97/4885NQO2 3756/4885MTNR1B 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.